Biomedical Engineering Reference
In-Depth Information
Green M, Loewenstein PM (1988) Autonomous functional domains of chemically synthesized
human immunodeficiency virus tat trans-activator protein. Cell 55 (6):1179-1188
Gregoriadis G (1978) Liposomes in the therapy of lysosomal storage diseases. Nature 275
(5682):695-696
Gupta B, Levchenko TS, Torchilin VP (2005) Intracellular delivery of large molecules and small
particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev 57 (4):637-651
Gupta B, Levchenko TS, Torchilin VP (2007) TAT peptide-modified liposomes provide enhanced
gene delivery to intracranial human brain tumor xenografts in nude mice. Oncol Res 16
(8):351-359
Hoekstra D, de Boer T, Klappe K, Wilschut J (1984) Fluorescence method for measuring the
kinetics of fusion between biological membranes. Biochemistry 23 (24):5675-5681
Jaracz S, Chen J, Kuznetsova LV, Ojima I (2005) Recent advances in tumor-targeting anticancer
drug conjugates. Bioorg Med Chem 13 (17):5043-5054
Jeang KT, Xiao H, Rich EA (1999) Multifaceted activities of the HIV-1 transactivator of transcrip-
tion, Tat. J Biol Chem 274 (41):28837-28840
Josephson L, Tung CH, Moore A, Weissleder R (1999) High-efficiency intracellular magnetic
labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem 10
(2):186-191
Kale AA, Torchilin VP (2007a) Design, synthesis, and characterization of pH-sensitive PEG-PE
conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the
hydrazone linkage on the ph stability of PEG-PE conjugates. Bioconjug Chem 18
(2):363-370
Kale AA, Torchilin VP (2007b) Enhanced transfection of tumor cells in vivo using “Smart” pH-
sensitive TAT-modified pegylated liposomes. J Drug Target 15 (7-8):538-545
Kirkegaard T, Jaattela M (2009) Lysosomal involvement in cell death and cancer. Biochim
Biophys Acta 1793 (4):746-754
Kleemann E, Neu M, Jekel N, Fink L, Schmehl T, Gessler T, Seeger W, Kissel T (2005) Nano-
carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to
PEG-PEI. J Control Release 109 (1-3):299-316
Ko YT, Hartner WC, Kale A, Torchilin VP (2009) Gene delivery into ischemic myocardium by
double-targeted lipoplexes with anti-myosin antibody and TAT peptide. Gene Ther 16
(1):52-59
Koshkaryev A, Thekkedath R, Pagano C, Meerovich I, VP T Specific lysosomal targeting by
liposomes modified with octadecyl-rhodamine B. In: 37th Annual Meeting and Exposition of
the Controlled Release Society, Portland, OR, USA, 2010
Kuwana T, Mullock BM, Luzio JP (1995) Identification of a lysosomal protein causing lipid
transfer, using a fluorescence assay designed to monitor membrane fusion between rat liver
endosomes and lysosomes. Biochem J 308 ( Pt 3):937-946
Lasic DD (1993) Liposomes: From Physics to Applications. Elsevier, Amsterdam
Lasic DD, Martin FJ (1995) Stealth Liposomes. CRC Press, Boca Raton
Levchenko TS, Rammohan R, Volodina N, Torchilin VP (2003) Tat peptide-mediated intracellular
delivery of liposomes. Methods Enzymol 372:339-349
Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT, Weissleder R (2000) Tat
peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor
cells. Nat Biotechnol 18 (4):410-414
Lukyanov AN, Hartner WC, Torchilin VP (2004) Increased accumulation of PEG-PE micelles in
the area of experimental myocardial infarction in rabbits. J Control Release 94 (1):187-193
Lukyanov AN, Torchilin VP (2004) Micelles from lipid derivatives of water-soluble polymers as
delivery systems for poorly soluble drugs. Adv Drug Deliv Rev 56 (9):1273-1289
Maeda H, Bharate GY, Daruwalla J (2009) Polymeric drugs for efficient tumor-targeted drug
delivery based on EPR-effect. Eur J Pharm Biopharm 71 (3):409-419
Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR
effect in macromolecular therapeutics: a review. J Control Release 65 (1-2):271-284
Search WWH ::
Custom Search